Sage, Biogen

Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage rejects Biogen takeover and launches review
Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results in the mid-stage KINETIC 2 study, while Sage has reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage sues Biogen after unsolicited takeover bid
Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results in the mid-stage KINETIC 2 study.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage Therapeutics,
FiercePharma10d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Sage rebuffs Biogen bid to take it over
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
BioSpace9h
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Sage Therapeutics price target raised to $9 from $6 at Mizuho
Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...